Comparable Disease Activity, Drug Persistence in Patients With JIA Who Switch to Biosimilars

Switching JIA patients from anti-TNF originators to biosimilars showed similar disease activity and drug persistence, with low switching back rates, supporting biosimilar safety and effectiveness.